Delving into the Latest Updates on Ancestim with Synapse

Overview

Basic Info

Drug Type

Colony-stimulating factors

Synonyms

Ancestim (USAN/INN), Ancestim (genetical recombination) (JAN), Human SCF

+ [5]

Target

CSF-3R

Mechanism

CSF-3R agonists(Colony stimulating factor 3 receptor agonists), Stem cells stimulants

Therapeutic Areas

Other Diseases

Active Indication

Hematopoietic stem cell transplantation

Inactive Indication-

Originator Organization

Amgen, Inc.

Active Organization

Amgen, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

AU (09 Aug 1999),

Hematopoietic stem cell transplantation

RegulationOrphan Drug (US)

Login to view timeline

Gene Sequence

Sequence Code 16915307

Source: *****

Some drugs have the ability to push stem cells (the cells responsible for producing new cell types) out of the bone marrow and into the blood stream. The steps involved in this process are still poorly understood. However, a better understanding of this process could lead to improved results in transplantation, cancer treatment, and contribute to the development of new genetic therapies for a wide variety of disorders.
In this study researchers plan to compare two different treatments, both that mobilize (push) stem cells out of the bone marrow into the blood stream. In addition, researchers will attempt to determine which is the most efficient at mobilizing blood cells of patients with multiple myeloma.
Information and knowledge gained from this study will help to design future transplantation and genetic therapy research studies.

Start Date01 Sep 1998

Sponsor / Collaborator

National Heart, Lung & Blood Institute

100 Clinical Results associated with Ancestim

Login to view more data

100 Translational Medicine associated with Ancestim

Login to view more data

100 Patents (Medical) associated with Ancestim

Login to view more data

935

Literatures (Medical) associated with Ancestim

01 Nov 2024·International Journal of Biological Macromolecules

Textural enhancement and glycemic potency reduction of sugarcane fiber-incorporated white bread with ascorbic acid and xanthan gum

Article

Author: Taheri, Afsaneh ; Abdul Halim, Fatin Natasha Binte ; Halim, Fatin Natasha Binte Abdul ; Du, Juan

In this study, ascorbic acid (0.02 % w/w), xanthan (0.75 % or 1.5 % w/w), and their combination have been added into sugarcane fiber (SCF) incorporated (5 % or 10 % w/w) wheat flour-based white breads. The effects of different additives on the physical characteristics, and the in-vitro and in-vivo glycemic potency of breads were evaluated. Addition of xanthan alone and the combination of additives reduced hardness and increased specific volume. SEM images showed that xanthan caused larger, more uneven holes in breadcrumbs due to xanthan's high elasticity and viscosity. FTIR spectrum indicated that the combination of SCF, xanthan, and ascorbic acid resulted in higher β-turn, lower α-helix protein structures, and lower ratios of α-helix/β-sheet, indicating a more flexible gluten structure formed. In-vitro digestibility results suggested that all SCF-incorporated breads had a lower glycemic index (GI) value than reference. Samples with 0.02 % (w/w) ascorbic acid and 1.5 % (w/w) xanthan reported the lowest in-vitro and in-vivo GI values.

01 Oct 2024·Macromolecular Rapid Communications

Lignin‐Based Carbon Fiber/Epoxy Resin Biocomposites with Excellent Fire Resistance and Mechanical Properties

Article

Author: Li, Jingwei ; Liu, Xiaobo ; Hu, Wei ; Liu, Zechi ; Zhao, Xiaojie ; Liu, Chengzhe ; Sun, Benhui ; Liu, Baijun ; Liu, Yuhan

AbstractCarbon fiber (CF)‐reinforced epoxy resin (EP) composites are lightweight materials with excellent comprehensive performance. However, the flammability of EP and the poor interfacial bonding between CF and EP are two key disadvantages that limit their further applications. Here, a kind of water‐soluble lignin‐based CF sizing agent (ELBEDK) is prepared through hydrophilic modification of enzymatic lignin, which can significantly enhance the interfacial interaction between CF and EP. Additionally, a highly efficient intumescent flame retardant (LMA) is prepared. The EP, enzymatic lignin, LMA and CF sized ELBEDK are compounded to obtain the fire‐safety CF reinforced composites (SCF/FEP/L). The flame retardancy of SCF/FEP/L with 7% LMA (SCF/FEP7) reached V‐0 rating. Moreover, SCF/FEP/L with 7% LMA and 15% lignin (SCF/FEP7/L15) present an limiting oxygen index (LOI)of 30.2% and V‐0 of UL‐94. Specifically, the total smoke production and the heat release rate are 47.8% and 46.81% lower than that of SCF/EP, respectively, indicating the improved smoke suppression and flame retardancy. The IFSS and flexural strength of SCF/FEP7/L15 are improved to be 59.4 MPa and 511.1 MPa, respectively. This study presents a simple approach to fabricate low‐cost high performance lignin‐based flame retardant CF/EP biocomposites with wide application potential.

23 Sep 2024·Polymers

High-Quality Foaming and Weight Reduction in Microcellular-Injection-Molded Polycarbonate Using Supercritical Fluid Carbon Dioxide under Gas Counter Pressure.

Article

Author: Agustion, Yogi Hendra ; Iskandar, Bermawi Priyatna ; Feng, Ching-Te ; Chen, Shia-Chung

Microcellular injection molding (MuCell^®) using supercritical fluid (SCF) as a foaming agent to achieve weight reduction has become popular in carbon emission reduction. In the typical MuCell® process, SCF N₂ is commonly used. Although SCF CO₂ exhibits high solubility and can achieve a high weight reduction, controlling the foaming is not easy, and its foaming cells are usually larger and less uniform, which limits its industrial application. Our previous studies have shown that gas counter pressure (GCP) can improve the foaming quality effectively. Here, we investigated whether or not the CO₂ SCF foaming quality could be improved, and weight reduction was achieved for polycarbonate (PC) material. This is quite important for the electronics industry, in which most of the housing for devices is made of PC materials. MuCell^® was subjected to molding experiments using the parameters of the SCF dosage, melt temperature, mold temperature, and injection speed. The results revealed that using CO₂ gas for the PC material can reduce the size of microcellular cells to 40 µm and increase the cell densities to 3.97 × 10⁶ cells/cm³. Using GCP significantly improved the microcellular injection-molded parts by reducing the cell size to 20.9 µm (a 45.41% improvement) and increasing the cell density to 8.04 × 10⁶ cells/cm³ (a 102.48% improvement). However, implementing GCP may slightly decrease the target weight reduction. This study reveals that microcellular injection molding of PC parts using SCF CO₂ can achieve high-quality foaming and reduce the weight by about 30%.

100 Deals associated with Ancestim

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02937	Ancestim	L03AA12	DB09103

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hematopoietic stem cell transplantation	AU	Amgen, Inc.	09 Aug 1999

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2004	Not Applicable	Relapsed Solid Neoplasm	-	rhTPO	(zlglrfohce) = wdtpgxzmer juzpuyhkva (kljtqucdse ) View more	-	15 Jul 2004
				rhIL-11 + G-SCF	(zlglrfohce) = lxhblgehxy juzpuyhkva (kljtqucdse ) View more